Tag Archives: RRMM

US FDA Approves Tecvayli® (Teclistamab-cqyv) for Relapsed/Refractory Multiple Myeloma (RRMM)

On October 25, 2022, the US FDA granted accelerated approval to Tecvayli® (teclistamab-cqyv, Janssen Biotech, Inc.) for adult patients with […]

October 28, 2022

Triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib for RRMM

According to phase-I/IIa findings from the ANCHOR (OP-104) trial that were introduced during the second EMN (European Myeloma Network) Meeting, […]

March 18, 2021